46 related articles for article (PubMed ID: 19299079)
1. Study of SFRP1 and SFRP2 methylation status in patients with de novo Acute Myeloblastic Leukemia.
Ghasemi A; Rostami S; Chahardouli B; Alizad Ghandforosh N; Ghotaslou A; Nadali F
Int J Hematol Oncol Stem Cell Res; 2015 Jan; 9(1):15-21. PubMed ID: 25802696
[TBL] [Abstract][Full Text] [Related]
2. Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic Modifications.
Schütt J; Nägler T; Schenk T; Brioli A
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439223
[TBL] [Abstract][Full Text] [Related]
3. SFRP4 is a prognostic marker and correlated with Treg cell infiltration in pancreatic ductal adenocarcinoma.
Yang MW; Tao LY; Yang JY; Jiang YS; Fu XL; Liu W; Huo YM; Li J; Zhang JF; Hua R; Qin XR; Sun YW; Liu DJ
Am J Cancer Res; 2019; 9(2):363-377. PubMed ID: 30906634
[TBL] [Abstract][Full Text] [Related]
4. Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options.
van Andel H; Kocemba KA; Spaargaren M; Pals ST
Leukemia; 2019 May; 33(5):1063-1075. PubMed ID: 30770859
[TBL] [Abstract][Full Text] [Related]
5. WNT Signaling in Cancer Immunosurveillance.
Galluzzi L; Spranger S; Fuchs E; López-Soto A
Trends Cell Biol; 2019 Jan; 29(1):44-65. PubMed ID: 30220580
[TBL] [Abstract][Full Text] [Related]
6. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
Tai YT; Cho SF; Anderson KC
Front Immunol; 2018; 9():1822. PubMed ID: 30147691
[TBL] [Abstract][Full Text] [Related]
7. Hypermethylation of secreted frizzled-related proteins predicts poor prognosis in non-M3 acute myeloid leukemia.
Guo H; Zhang TJ; Wen XM; Zhou JD; Ma JC; An C; Zhang W; Xu ZJ; Lin J; Qian J
Onco Targets Ther; 2017; 10():3635-3644. PubMed ID: 28790854
[TBL] [Abstract][Full Text] [Related]
8. β-catenin induces expression of prohibitin gene in acute leukemic cells.
Kim DM; Jang H; Shin MG; Kim JH; Shin SM; Min SH; Kim IC
Oncol Rep; 2017 Jun; 37(6):3201-3208. PubMed ID: 28440457
[TBL] [Abstract][Full Text] [Related]
9. Aberrantly expressed LGR4 empowers Wnt signaling in multiple myeloma by hijacking osteoblast-derived R-spondins.
van Andel H; Ren Z; Koopmans I; Joosten SP; Kocemba KA; de Lau W; Kersten MJ; de Bruin AM; Guikema JE; Clevers H; Spaargaren M; Pals ST
Proc Natl Acad Sci U S A; 2017 Jan; 114(2):376-381. PubMed ID: 28028233
[TBL] [Abstract][Full Text] [Related]
10. Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease.
van Andel H; Kocemba KA; de Haan-Kramer A; Mellink CH; Piwowar M; Broijl A; van Duin M; Sonneveld P; Maurice MM; Kersten MJ; Spaargaren M; Pals ST
Oncogene; 2017 Apr; 36(15):2105-2115. PubMed ID: 27775078
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of DNA methyltransferase-1 inhibits proliferation and derepresses tumor suppressor genes in myeloma cells.
Zhou W; Chen H; Hong X; Niu X; Lu Q
Oncol Lett; 2014 Nov; 8(5):2130-2134. PubMed ID: 25289094
[TBL] [Abstract][Full Text] [Related]
12. Secreted frizzled‑related protein 2 is epigenetically silenced and functions as a tumor suppressor in oral squamous cell carcinoma.
Xiao C; Wang L; Zhu L; Zhang C; Zhou J
Mol Med Rep; 2014 Nov; 10(5):2293-8. PubMed ID: 25189527
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic modulating agents as a new therapeutic approach in multiple myeloma.
Maes K; Menu E; Van Valckenborgh E; Van Riet I; Vanderkerken K; De Bruyne E
Cancers (Basel); 2013 Apr; 5(2):430-61. PubMed ID: 24216985
[TBL] [Abstract][Full Text] [Related]
14. The Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells.
Ford CE; Jary E; Ma SS; Nixdorf S; Heinzelmann-Schwarz VA; Ward RL
PLoS One; 2013; 8(1):e54362. PubMed ID: 23326605
[TBL] [Abstract][Full Text] [Related]
15. Promoter methylation of Wnt antagonists DKK1 and SFRP1 is associated with opposing tumor subtypes in two large populations of colorectal cancer patients.
Rawson JB; Manno M; Mrkonjic M; Daftary D; Dicks E; Buchanan DD; Younghusband HB; Parfrey PS; Young JP; Pollett A; Green RC; Gallinger S; McLaughlin JR; Knight JA; Bapat B
Carcinogenesis; 2011 May; 32(5):741-7. PubMed ID: 21304055
[TBL] [Abstract][Full Text] [Related]
16. Pharmaceutical inhibition of glycogen synthetase kinase-3β reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model.
Gunn WG; Krause U; Lee N; Gregory CA
Blood; 2011 Feb; 117(5):1641-51. PubMed ID: 21123822
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic dysregulation of secreted Frizzled-related proteins in multiple myeloma.
Jost E; Gezer D; Wilop S; Suzuki H; Herman JG; Osieka R; Galm O
Cancer Lett; 2009 Aug; 281(1):24-31. PubMed ID: 19299079
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic inactivation of secreted Frizzled-related proteins in acute myeloid leukaemia.
Jost E; Schmid J; Wilop S; Schubert C; Suzuki H; Herman JG; Osieka R; Galm O
Br J Haematol; 2008 Sep; 142(5):745-53. PubMed ID: 18537968
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma.
Chim CS; Pang R; Fung TK; Choi CL; Liang R
Leukemia; 2007 Dec; 21(12):2527-36. PubMed ID: 17882284
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
